ArriVent BioPharma
AVBP
121 hedge funds and large institutions have $810M invested in ArriVent BioPharma in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 15 closing their positions.
61,858% more call options, than puts
Call options by funds: $7.43M | Put options by funds: $12K
100% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 15
14% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 35
14% more funds holding
Funds holding: 106 → 121 (+15)
14% more capital invested
Capital invested by funds: $712M → $810M (+$97.8M)
2.07% more ownership
Funds ownership: 95.07% → 97.14% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$9.54M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$8.38M |
| 3 |
BlackRock
New York
|
+$6.8M |
| 4 |
Goldman Sachs
New York
|
+$6.46M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$12.9M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$11.6M |
| 3 |
CLG
Cooperman Leon G
|
-$7.77M |
| 4 |
Morgan Stanley
New York
|
-$6.13M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$4.73M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Verition Fund Management
Greenwich,
Connecticut
| – | -$278K | -15,045 | Closed |
|
|
CM
127
Caption Management
Oklahoma City,
Oklahoma
| – | -$129K | -7,000 | Closed |
|
128
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$67.8K | -3,258 | Closed |
|
|
WC
129
Wexford Capital
West Palm Beach,
Florida
| – | -$28.9K | -1,567 | Closed |
|
130
Bessemer Group
Woodbridge,
New Jersey
| – | -$29K | -1,395 | Closed |
|
|
PA
131
Parallel Advisors
San Francisco,
California
| – | -$1.51K | -82 | Closed |
|
|
PS
132
Principal Securities
Des Moines,
Iowa
| – | -$295 | -16 | Closed |
|
|
MA
133
Montag & Associates
Atlanta,
Georgia
| – | -$203 | -11 | Closed |
|
|
CA
134
Clearstead Advisors
Cleveland,
Ohio
| – | -$19 | -1 | Closed |
|
|
C
135
Covestor
London,
United Kingdom
| – | -$21 | -1 | -9% |
|
|
IA
136
IFP Advisors
Tampa,
Florida
| – | -$18 | -1 | Closed |
|
AVBP Hedge Fund Activity: Q4 2025 in Review
121 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q4 2025, worth a combined $810M — up 14% from $712M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new AVBP positions and 15 closed out — a net gain of 15 holders — while 40 added to existing stakes and 35 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $9.54M. The largest seller was Siren LLC, exiting entirely with an estimated $12.9M sold.
- 121 institutional investors held ArriVent BioPharma (AVBP) as of Q4 2025, up from 106 in Q3 2025.
- Funds reported $810M of ArriVent BioPharma stock for Q4 2025, up 14% quarter-over-quarter.
- 30 funds opened new ArriVent BioPharma positions in Q4 2025 and 15 closed out, a net change of +15 holders.
- The largest ArriVent BioPharma buyer in Q4 2025 was Citadel Advisors, an estimated $9.54M added.
- The largest ArriVent BioPharma seller in Q4 2025 was Siren LLC, an estimated $12.9M sold.
Based on aggregated 13F filings for Q4 2025.